National Organization for Rare Disorders Announces More Than $100,000 in Grant Funding Available for Rare Disease Research
19 Sep 2023
Three New RFPs Now Open for Qualified Researchers of AVM, LYS, and MMIHS
DANBURY, Conn., Sept. 19, 2023 /PRNewswire/ -- The National Organization for Rare Disorders (NORD®) announced three new grant funding opportunities related to the following rare diseases: Arteriovenous Malformation (AVM), Levy-Yeboa Syndrome (LYS), and Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS).
NORD's Research Grants Program provides seed-money grants to qualified investigators for scientific and clinical research into diseases for which there are few other sources of funding. These grants are competitive and international.
Continue Reading
The National Organization for Rare Disorders (NORD) announces three new research opportunities for AVM, LYS, and MMIHS.
Tweet this
Preview
Source: PRNewswire
Photo of a medical researcher looking through a microscope
With funding from the Tyler James Abizeid Foundation, NORD is accepting applications for one grant of
up to $35,000 US, for scientific and/or clinical research studies related to Arteriovenous Malformation (AVM). Deadline for initial applications is
Monday, October 16. View more information and apply here.
With funding by the Maxwell Family, NORD is accepting applications for one grant of
up to $40,000 US, for scientific and/or clinical research studies related to Levy-Yeboa syndrome (LYS). Deadline for initial applications is
Monday, October 16. View more information and apply here.
With funding from the MMIHS Foundation, NORD is accepting applications for
one grant of $30,000 US for scientific and/or clinical research studies related to megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS). Deadline for initial applications is
Monday, October 16. View more information and apply here.
Grants will be awarded to qualified researchers to initiate small scientific research studies or clinical trials, the results of which could be used to obtain funding from the NIH, FDA, or other funding agencies, or to attract a corporate sponsor.
"Since 1989, NORD's grants have led to the development of two FDA-approved treatments and many peer-reviewed publications. Over 200 grants have been awarded, totaling over $9 million in approved funding. The vision behind these critical study grants is to ultimately lead to new diagnostics, treatments, and cures for rare diseases," said Aliza Fink, Director, Research Programs, NORD.
To learn more or submit to the 2023 NORD Research Grants Cycle, visit rarediseases.org/advancing-research/request-for-proposals/
About the National Organization for Rare Disorders (NORD)
With a 40-year history of advancing care, treatments and policy, the National Organization for Rare Disorders (NORD) is the leading and longest-standing patient advocacy group for the 25-30 million Americans living with a rare disease. NORD, a 501(c)(3) nonprofit, is dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 330 patient organization members, is committed to improving the health and well-being of people with rare diseases by driving advances in care, research and policy. For more information, please visit https://rarediseases.org/.
SOURCE National Organization for Rare Disorders (NORD)
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.